Open Access
Review

Human monoclonal antibodies in cancer therapy: a review of recent developments

Lin Xin1,*,Jiaqing Cao1,Hua Cheng1,Fei Zeng1,Xiaoyun Hu1,Jianghua Shao1
1
Department of General Surgery, The Second Affiliated Hospital of NanChang University, 330006 Nanchang, Jiangxi, China
DOI: 10.2741/4139 Volume 18 Issue 2, pp.765-772
Published: 01 January 2013
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
*Corresponding Author(s):  
Lin Xin
E-mail:  
xinlindoc@yeah.net
Abstract

In the last decade, phage-display technology for the generation of monoclonal antibodies (mAbs) has improved significantly. Several novel human mAbs directed to a wide range of targets have been generated for the treatment of common malignancies. These targets include antigens associated with apoptosis, angiogenesis and solid tumors, as well as tumor growth-related antigens, insulin-like growth factor I receptor and hepatocyte growth factor. The safety, pharmacokinetics, and pharmacodynamics of several human mAbs have been evaluated in patients with advanced solid tumors. In conclusion, significant advances in the generation and application of human mAbs in cancer therapy have been made in the last decade.

Key words

Monoclonal antibodies, Ab-dependent cellular cytotoxicity, TRAIL-R1, Review

Share and Cite
Lin Xin, Jiaqing Cao, Hua Cheng, Fei Zeng, Xiaoyun Hu, Jianghua Shao. Human monoclonal antibodies in cancer therapy: a review of recent developments. Frontiers in Bioscience-Landmark. 2013. 18(2); 765-772.